Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention

Muthiah Vaduganathan(Brigham and Women's Hospital), Franz Weidinger(Austrian Competence Centre of Food Safety), C. Michael Gibson(Baim Institute for Clinical Research), Deepak L. Bhatt(Mount Sinai Hospital), Christian W. Hamm(Justus-Liebig-Universität Gießen), Nick Bett, Jeffrey Lefkovits(The Alfred Hospital), G. Nelson(Columbia University Irving Medical Center), John D. Horowitz(Basil Hetzel Institute), Fernando Cura, Philip E. Aylward(Flinders Medical Centre), Brendan Gunalingam(St Vincent's Hospital Sydney), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Harry C. Lowe(Concord Repatriation General Hospital), Rohan Jayasinghe, Gregg W. Stone(Cardiovascular Institute of the South), Johann Altenberger(University of Belgrade), Ron Lehman, M Ballarino, Con Aroney, Steven Elkin(Doctors Company (United States)), Robert A. Harrington(Clinical Research Institute), Harvey D. White(University of Auckland), Efthymios Deliargyris(CytoSorbents (United States)), H. Hallani(Liverpool Hospital), Matthew J. Price(Scripps Clinic), F Leisch(Women's General Hospital), Kurt Huber(Sigmund Freud Privatuniversität Wien), Aníbal Damonte, Jayne Prats(Doctors Company (United States)), Alberto Menozzi(Ospedale di Parma), Craig Jeurgens, Raibhan Yadav, Phil Roberts-Thomson, Peter Thompson, Thomas Neunteufl, Stephen Duffy, Diego Grinfeld, Gishel New, Georg Gaul, D. Cross, M. Worthley(Scripps Clinic), Jaime Rankin, Ronald Dick(Capital Medical University), Carlos Alejandro Álvarez, A. Farshid(Clinical Trial Investigators), P. Garrahy, Philippe Gabríel Steg(Mount Sinai Hospital)
Journal of the American College of Cardiology
January 1, 2017
Cited by 57


Related Papers